Prognostic Impact of Pretreatment Albumin to Globulin Ratio in Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin ’s lymphoma, representing about 30% of cases [1]. The introduction of rituximab (R) in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) chemotherapy, known as “R-CHOP”, improves survival outcomes [2,3], and has affected the importance of formerly recognized prognostic markers [4]. In the pre-R era, the International Prognostic Index (IPI) was used to predict responses and prognoses in patients with high-risk non-Hodgkin’s lymphoma [5].
Source: Leukemia Research - Category: Hematology Authors: Seok-Hyun Kim, Se-Il Go, Jangho Seo, Myoung Hee Kang, Sung Woo Park, Hoon-Gu Kim, Gyeong-Won Lee Source Type: research